Drugs / Fulacimstat
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03402438 | Feb → Dec 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT03412006 | Feb 2018 → Oct 2019 | diabetic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT02976467 | Dec 2016 → Jul 2018 | myocardial infarction | Bayer | Completed | Missed primary |
| Phase 2 | NCT02452515 | Jul 2015 → Jan 2016 | heart failure | Bayer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fulacimstat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02976467 ↗ |
| Known as | BAY1142524 | “Fulacimstat (BAY1142524)” NCT03402438 ↗ |
| Action | Inhibit | “the chymase inhibitor BAY1142524” NCT02452515 ↗1“Chymase inhibitor” CHEMBL4297596 ↗ |
| Modality | Small molecule | — CHEMBL4297596 ↗ |
| Route | Oral | “14 Day Oral Treatment With Different Doses of the Chymase Inhibitor BAY1142524” NCT02452515 ↗ |
| Target | CMA1 | “Chymase inhibitor” CHEMBL4297596 ↗ |